Alpha Cognition Inc. (ACOG) Earnings Call Transcripts

Alpha Cognition Inc.'s Latest Earnings Call - Q4 FY2025

In the fourth quarter and full year fiscal 2025, Alpha Cognition Inc. (ACOG:US) reported total revenues of $2.8 million, driven primarily by net product sales of $2.5 million from ZUNVEYL, the company's oral treatment for Alzheimer's disease. For the full year, total revenue reached $10.2 million. Management highlighted strong demand indicators, including a 62% quarter-over-quarter growth in bottles dispensed and a significant increase in prescriber engagement, which positions the company for continued growth in 2026. However, operating expenses rose sharply to $10.7 million for the quarter, resulting in a net loss of $6.9 million, raising concerns about future profitability despite a solid cash position of $66 million.

Reported metrics

Guidance from management

Management did not provide formal revenue guidance for 2026 but expects continued sequential growth in ZUNVEYL sales as physician awareness and payer access increase. Operating expenses are projected to be between $54 million and $58 million for the full year 2026.

What management said

Okay. Thanks, everybody, for attending the call today. I think you've heard our focus for 2026. I'll just reiterate, we plan to continue to focus on sales execution. We plan to focus on payer coverage and improvement in ZUNVEYL coverage with our payers. While doing that, we'll work diligently to complete our studies on time and with high quality and advance our R&D pipeline. And along with all of that, as we have don...

What analysts pressed on

Analysts expressed concerns regarding the high operating expenses and the timeline for achieving profitability. There were questions about the pace of payer conversions and the potential impact on sales growth as the company expands its prescriber base into neurology.

Main topics on the call

• Strong Demand Growth for ZUNVEYL — Alpha Cognition reported dispensing 4,941 bottles of ZUNVEYL in Q4, marking a 62% increase quarter-over-quarter. CEO Michael McFadden stated, 'We believe ZUNVEYL is moving beyond initial trial use and becoming embedded i...
• Expansion of Payer Access — The company signed a second national PBM contract, achieving coverage with 2 of the top 4 PBMs. McFadden noted, 'Payer access remains a major friction point with prescription approvals, but it also presents a major oppor...
• Increased Operating Expenses — Total operating expenses for Q4 were $10.7 million, significantly higher than $2.7 million in the same quarter last year. CFO Henry Du remarked, 'The year-over-year increase primarily reflects higher SG&A expenses associ...
• Focus on Clinical Studies — The company announced three real-world studies to be initiated in 2026, aimed at strengthening ZUNVEYL's positioning with payers. McFadden stated, 'We believe these data will be differentiating with our customers as ther...

Read the full Alpha Cognition Inc. transcript (Q4 FY2025) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 9 Alpha Cognition Inc. earnings call transcripts on record, spanning January 28, 2025 to August 13, 2026. Based on this history, Alpha Cognition Inc. reports quarterly. The most recent call on file is dated August 13, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

ACOG

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

9

First call

January 28, 2025

Most recent

August 13, 2026

Reporting cadence

quarterly